星空体育官方入口网站网址大全-登录入口官网

#依维莫司#

1篇内容 | 1262人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=2199680, encodeId=b402219968093, content=<a href='/topic/show?id=d3b326916c3' target=_blank style='color:#2F92EE;'>#依维莫司#</a> <a href='/topic/show?id=93df1025e1f6' target=_blank style='color:#2F92EE;'>#高级别浆液性卵巢癌#</a> <a href='/topic/show?id=c8cb113606d9' target=_blank style='color:#2F92EE;'>#铂耐药#</a>, objectTitle=铂耐药高级别浆液性卵巢癌患者检出TSC2基因变异，获益依维莫司, objectType=article, longId=822443, objectId=e86e82244350, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/Random/black-surgeon-giving-instruction-to-medical-team-TMPFGNZ.jpg, objectUrl=/article/show_article.do?id=e86e82244350, replyNumber=0, likeNumber=29, createdTime=2024-04-21, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=e86e82244350, moduleTitle=铂耐药高级别浆液性卵巢癌患者检出TSC2基因变异，获益依维莫司, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=e86e82244350)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2189260, encodeId=a2c72189260e0, content=<a href='/topic/show?id=7c328264677' target=_blank style='color:#2F92EE;'>#肾细胞癌#</a> <a href='/topic/show?id=d3b326916c3' target=_blank style='color:#2F92EE;'>#依维莫司#</a> <a href='/topic/show?id=001b61108cc' target=_blank style='color:#2F92EE;'>#术后辅助治疗#</a>, objectTitle=Lancet：肾细胞癌术后辅助依维莫司（EVEREST）：一项随机、双盲、安慰剂对照3期试验, objectType=article, longId=814635, objectId=097881463572, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20240225/1708833368724_6145188.jpg, objectUrl=/article/show_article.do?id=097881463572, replyNumber=0, likeNumber=42, createdTime=2024-02-25, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=威斯康星, moduleDTOList=[ModuleDTO(moduleId=097881463572, moduleTitle=Lancet：肾细胞癌术后辅助依维莫司（EVEREST）：一项随机、双盲、安慰剂对照3期试验, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=097881463572)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2184586, encodeId=64e7218458613, content=<a href='/topic/show?id=d3b326916c3' target=_blank style='color:#2F92EE;'>#依维莫司#</a> <a href='/topic/show?id=25a21106626c' target=_blank style='color:#2F92EE;'>#Belzutifan#</a> <a href='/topic/show?id=c193110640f1' target=_blank style='color:#2F92EE;'>#ASCO GU 2024#</a> <a href='/topic/show?id=825911066391' target=_blank style='color:#2F92EE;'>#晚期RCC#</a>, objectTitle=ASCO GU 2024：Belzutifan与依维莫司对晚期RCC的疗效：LITESPARK-005 3 期研究中的患者报告结果 (PROs), objectType=article, longId=811387, objectId=195281138e2f, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20240128/1706443016945_8624274.png, objectUrl=/article/show_article.do?id=195281138e2f, replyNumber=0, likeNumber=52, createdTime=2024-01-29, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=195281138e2f, moduleTitle=ASCO GU 2024：Belzutifan与依维莫司对晚期RCC的疗效：LITESPARK-005 3 期研究中的患者报告结果 (PROs), moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=195281138e2f)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2175800, encodeId=d5e321e580083, content=<a href='/topic/show?id=53668406668' target=_blank style='color:#2F92EE;'>#胶质瘤#</a> <a href='/topic/show?id=d3b326916c3' target=_blank style='color:#2F92EE;'>#依维莫司#</a> <a href='/topic/show?id=33aa2631601' target=_blank style='color:#2F92EE;'>#低级别胶质瘤#</a>, objectTitle=JCO：依维莫司在复发或进展性儿童低级别胶质瘤中呈现疗效, objectType=article, longId=805742, objectId=ff56805e42e4, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/Random/adhd_children_s6_adhd_symptoms.jpg, objectUrl=/article/show_article.do?id=ff56805e42e4, replyNumber=0, likeNumber=72, createdTime=2023-12-19, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=ff56805e42e4, moduleTitle=JCO：依维莫司在复发或进展性儿童低级别胶质瘤中呈现疗效, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=ff56805e42e4)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2175468, encodeId=08eb21e54687f, content=<a href='/topic/show?id=d3b326916c3' target=_blank style='color:#2F92EE;'>#依维莫司#</a> <a href='/topic/show?id=376e2818141' target=_blank style='color:#2F92EE;'>#儿童低级别胶质瘤#</a>, objectTitle=JCO：依维莫司在复发或进展性儿童低级别胶质瘤中呈现疗效！, objectType=article, longId=804496, objectId=10ae804496b0, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/Random/medics-and-patient-on-hospital-gurney-at-PMW6NAQ.jpg, objectUrl=/article/show_article.do?id=10ae804496b0, replyNumber=0, likeNumber=56, createdTime=2023-12-17, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=10ae804496b0, moduleTitle=JCO：依维莫司在复发或进展性儿童低级别胶质瘤中呈现疗效！, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=10ae804496b0)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=1004497, encodeId=73c2100449e26, content=<a href='/topic/show?id=d3b326916c3' target=_blank style='color:#2F92EE;'>#依维莫司#</a>Lenvatinib联合依维莫司在晚期nccRCC患者中显示出良好的抗癌活性，且安全性与研究药物联合用药的既定安全性一致，值得未来进一步研究。, objectTitle=依维莫司, objectType=topic, longId=26916, objectId=null, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=null, replyNumber=0, likeNumber=117, createdTime=2021-08-01, rootId=0, userName=yangchou, userId=88b489038, projectId=1, avatar=, status=1, hasArticle=0, attachment=null, ipAttribution=, moduleDTOList=null, followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

依维莫司

2020-05-29

梅斯管理员 (审核中...)

前往app查看评论内容

#依维莫司# #高级别浆液性卵巢癌# #铂耐药#

铂耐药高级别浆液性卵巢癌患者检出TSC2基因变异，获益依维莫司

2024-04-21发表于上海

梅斯管理员 (审核中...)

前往app查看评论内容

#肾细胞癌# #依维莫司# #术后辅助治疗#

Lancet：肾细胞癌术后辅助依维莫司（EVEREST）：一项随机、双盲、安慰剂对照3期试验

2024-02-25发表于威斯康星

梅斯管理员 (审核中...)

前往app查看评论内容

#依维莫司# #Belzutifan# #ASCO GU 2024# #晚期RCC#

ASCO GU 2024：Belzutifan与依维莫司对晚期RCC的疗效：LITESPARK-005 3 期研究中的患者报告结果 (PROs)

2024-01-29发表于上海

梅斯管理员 (审核中...)

前往app查看评论内容

#胶质瘤# #依维莫司# #低级别胶质瘤#

JCO：依维莫司在复发或进展性儿童低级别胶质瘤中呈现疗效

2023-12-19发表于上海

梅斯管理员 (审核中...)

前往app查看评论内容

#依维莫司# #儿童低级别胶质瘤#

JCO：依维莫司在复发或进展性儿童低级别胶质瘤中呈现疗效！

2023-12-17发表于上海

yangchou (审核中...)

前往app查看评论内容

#依维莫司#Lenvatinib联合依维莫司在晚期nccRCC患者中显示出良好的抗癌活性，且安全性与研究药物联合用药的既定安全性一致，值得未来进一步研究。

2021-08-01

科室
- - 订阅+
  - 更多科室
工具
服务